Clinical validation of breast cancer biomarkers using tissue microarray technology

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 1, 2007, Pages 45-49

  Quraishi, Iram ^a,e   Rishi, Mazhar ^c   Feldman, Michael ^b   Wargovich, Michael J ^d   Weber, Barbara ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c Via Christi Rehabilitation Center   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer progression tissue microarrays; DNA microarrays; Immunohistochemistry; Prostatic specific antigen

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RECEPTOR ANTIBODY; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOMA IN SITU; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TISSUE MICROARRAY; VALIDATION STUDY;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247642336     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213129.86288.34     Document Type: Article

References (21)

1. Wright GL Jr. Monoclonal antibody (anti-Leu 7) directed against natural killer cells reacts with normal, benign and malignant prostate tissues. Int J Cancer. 1985;36:677-683.
2. Kononen J, Bullard M, Kallioniemi OP. Tissue microarrays for high through put molecular profiling of tumor specimens. J Nature Med. 1998;4:844-847.
3. Kallioniemi O-P, Wagnur U, Kononen J. Tissue microarray technology for high through-put molecular profiling of cancer. Human Mol Genet. 2001;10:657-662.
4. Bubendorf L. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999;59:803-806. Erratum in: Cancer Res. 1999;59:1388.
5. Moch H, Kallioniemi OP, Sautér G. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol. 2001;8:14-20.
6. Horvarth L, Henshall S. Timely topic: the application of tissue microarray to cancer research. Pathology. 2001;33:125-129.
7. Bubendorf L, Nacito A, Moch H. Tissue microarray technology. J Pathol. 2001;195:72-79.
8. Torhorst J, Baucher C, Sauter G, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256.
9. Sallinen S-L, Sallinen PK, Haapasalo HK. Identification of differentially expressed genes in human gloimas by DNA microarrays and tissue chip techniques. Cancer Res. 2000;60:6617-6622.
10. Camp RL. Validation of TMA in breast carcinoma. Lab Invest. 2000;80:1943-1949.
11. Brooks SA, Lathem AJ. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J. 1995;27:689-693.
12. Cardillo MR. Molecular genetic analysis of TGF beta1 in the breast cancer. J Exp Clin Cancer Res. 1997;16:57-63.
13. Schena M. Quantitative monitoring of gene expression patterns with a cDNA microarray. Science. 1995;270:467-470.
14. Rimm DL, Camp RL, Provost E. Amplification of tissue construction by tissue microarray. Exp Mol Pathol. 2001;70:255-264.
15. Leong AS-Y. Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave antigen retrieval. Appl Immunohistochem. 1993;1:282-288.
16. Kooper K, Haffajee Z. bcl-2 and p53 protein expression in follicular lymphoma. J Pathol. 1997;182:307-310.
17. Yu H, Berkel H. Prostate-specific antigen in women. J La State Med Soc. 1999;151:209-213.
18. Mitchell G, Sibley PE, Eeles RA. Prostate-specific antigen in nipple aspirate fluid: menstrual cycle variability and correlation with serum specific antigen. Tumour Biol. 2002;23:287-297.
19. Alanen KA, Kuopio T, Nevalainen TJ. Immunohistochemical labeling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat. 1999;56:169-176.
20. Heyl W, Wolff Jm, Rath W. Immunohistochemical analysis of prostate specific antigen does not correlate to other prognostic factors in breast cancer. Anticancer Res. 1999;19:2563-2565.
21. Bova GS, Parmigiani G, Epstein JI. Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum Pathol. 2001;32:417-427.